- NurExone Biologic (NRX) is presenting at the conference “Understanding Extracellular Vesicle Biogenesis and Composition for Detection and Treatment of Diseases”, hosted by Gordon Research Conference’s (“GRC”) in Newry, Maine
- Diving into the rapidly growing space of extracellular vesicles and extracellular RNA while bringing in a variety of clinical investigators
- NurExone (NRX) is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries
- NurExone (NRX) remains unchanged on the day, trading at C$0.38 at 2:41 PM ET
NurExone Biologic (NRX) is presenting at the conference “Understanding Extracellular Vesicle Biogenesis and Composition for Detection and Treatment of Diseases”.
The conference is being hosted by Gordon Research Conference’s (GRC) in Newry, Maine.
The goal of this conference is to dive into the rapidly growing space of extracellular vesicles and extracellular RNA while bringing in a variety of clinical investigators who are experts in the field. The conference (July 24 until July 29) will explore the impact that extracellular vesicles (EVs) have on maintaining health, tissue regeneration and more.
NurExone is one of the sponsors of the conference and will set up an in-depth poster presentation detailing its revolutionary ExoPTEN technology and the role it plays in spinal cord regeneration. The presentation covers the science behind exosomes, offers several proofs-of-concept, and demonstrates how the intranasal treatment leads to locomotor, sensory, and bladder recovery.
Dr. Lior Shaltiel, CEO of NurExone says:
“GRC offers a distinguished international forum for the latest scientific developments and we are excited to be included in the 2022 Extracellular Vesicles Conference to showcase our innovative exosome-based technology. The conference will provide us with the opportunity to raise awareness about the promise of nanocarriers for drug delivery and targeted therapy, in front of an international audience consisting of renowned scientists and experts in the field of extracellular vesicles.”
NurExone Biologic (NRX) is a pharmaceutical company developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
NurExone (NRX) remains unchanged on the day, trading at C$0.38 at 2:41 PM ET.
.